lapatinib has been researched along with Uterine Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muggia, F; Teplinsky, E | 1 |
| Borger, DR; Byron, VF; DiGloria, CM; Foster, R; Groeneweg, JW; Growdon, WB; Hernandez, SF; Kim, M; Lopez, H; Rueda, BR; Scialabba, V; Tambouret, R; Zhang, L | 1 |
| Borger, D; Chisholm, S; Foster, R; Growdon, WB; Hernandez, SF; Rueda, BR | 1 |
| Bai, Y; Black, J; Carvajal-Hausdorf, DE; Rimm, DL; Santin, AD; Schalper, KA | 1 |
1 review(s) available for lapatinib and Uterine Neoplasms
| Article | Year |
|---|---|
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
3 other study(ies) available for lapatinib and Uterine Neoplasms
| Article | Year |
|---|---|
Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Tumor Burden; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Cell Cycle; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Cystadenoma, Serous; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Extracellular Space; Female; Fluorescent Antibody Technique; Humans; Intracellular Space; Lapatinib; Maytansine; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Protein Domains; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Tissue Array Analysis; Trastuzumab; Uterine Neoplasms | 2017 |